oseltamivir / Generic mfg. - LARVOL DELTA

Influenza as a less commonly recognized cause of hemophagocytic lymphohistiocytosis: A systematic review of case reports and case series (ASH 2025) - "Antiviral therapy was administered in 89.5% patients, most commonly with Oseltamivir (88.2%).Seventeen percent of patients were diagnosed with HLH post-mortem and therefore did not receive HLH-directed therapy. Seventy-seven percent received corticosteroids, 36% received intravenousimmunoglobulin (IVIG), one patient received rituximab, and another patient underwent plasmapheresis.Etoposide was administered to 9 patients, and cyclosporine to 2 patients...Survival appeared generally favorableamong patients who received antiviral and/or immunosuppressive therapy. Further studies arenecessary to establish standardized diagnostic and therapeutic protocols for influenza-associated HLH."

Case report • Clinical • Review • Dyslipidemia • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hypertriglyceridemia • Immunology • Infectious Disease • Influenza • Rare Diseases • Respiratory Diseases • Thrombocytopenia • IL2 • ISG20 • PRF1

Influenza A-Associated Acute Necrotizing Encephalopathy in An Immunocompetent Adult. (PubMed, Eur J Case Rep Intern Med) - "Acute necrotizing encephalopathy (ANE) in the setting of Influenza A infection clinically manifests with high-grade fever and neurological semiology, including diplopia and epileptic episodes as seen in this patient.Core therapeutic management of ANE involves the administration of oseltamivir, intravenous corticosteroids and gamma globulin.The present case report underlines the abrupt clinical deterioration of an immunocompetent patient with Influenza A-induced ANE, over a 3-day onset of flu-like symptoms."

Journal • CNS Disorders • Epilepsy • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance. (PubMed, Nat Commun) - "More importantly, we demonstrate that the HA-K130N can enhance the oseltamivir resistance conferred by the well-characterized NA-N295S mutation. Our study provides essential evidence that mutations in HA are closely associated with the occurrence of neuraminidase inhibitor resistance, highlighting the urgent need for global monitoring and assessment of oseltamivir-resistant mutations in the HA protein, in addition to NA, during the ongoing H1N1 epidemics."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection. (PubMed, Antivir Ther) - "We recently reported that the combination of AN-137B, a molecular analogue of PDX, with oseltamivir or baloxavir provided synergism/additive effects against influenza, in vitro. In the latter group, the mean lung viral titre (LVT), as determined by plaque assay (2.53 ± 0.63 × 105 PFU/mL) and by qRT-PCR (2.39 ± 1.3 × 108 copies/mL), was significantly lower than that of the untreated group (4.76 ± 0.9 × 105 PFU/mL and 3.75 ± 0.86 × 108 copies/mL (p < .05), contrasting with LVTs of animals that received single therapies. These in vivo results reinforce the potential of AN-137B when combined to a potent anti-influenza agent against severe influenza."

Journal • Preclinical • Infectious Disease • Inflammation • Influenza • Respiratory Diseases • PD-1

Comparison of clinical outcomes of oseltamivir versus baloxavir in outpatients with influenza: a retrospective cohort analysis. (PubMed, Int J Infect Dis) - "Conclusions The outpatients with treatment of baloxavir have lower hospitalization rates and emergency department visits. Mortality rates were nearly identical between groups, showing no significant difference."

Clinical data • Journal • Retrospective data • Infectious Disease • Influenza • Respiratory Diseases

Expansion of influenza A(H1N1)pdm09 NA:S247N viruses with reduced susceptibility to oseltamivir, Catalonia, Spain, and in Europe, July to October 2025. (PubMed, Euro Surveill) - "The mutation, conferring reduced susceptibility to oseltamivir, was phenotypically confirmed (IC50 between 0.82 and 1.63 nM, compared to median IC50 of 0.3 nM for susceptible strains). An increased proportion of S247N variants was also observed in sequence data (10,944 sequences) from other parts of Spain and five of 35 submitting countries across Europe."

Journal • Infectious Disease • Influenza • Respiratory Diseases

RETRACTION: Lianhua-Qingwen Displays Antiviral and Anti-Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. (PubMed, Evid Based Complement Alternat Med) - "[This retracts the article DOI: 10.1155/2020/3196375.]."

Journal • Preclinical • Infectious Disease • Influenza • Respiratory Diseases

Elucidating the nature of the interactions of oseltamivir with the 2D model of influenza A virus lipid envelope. (PubMed, Colloids Surf B Biointerfaces) - "BAM and GIXD studies further demonstrated that OSL hinders the formation of condensed DMPS domains. These findings are crucial for understanding antiviral-lipid envelope mechanisms and designing novel targeted therapies."

Journal • Infectious Disease • Influenza • Respiratory Diseases

A literature review of influenza chemoprophylaxis and treatment in children. (PubMed, Germs) - "In Europe, oseltamivir, zanamivir, and baloxavir marboxil are recommended for the treatment or prophylaxis of influenza in adults and children, while the Food and Drug Administration added intravenous peramivir to the list of anti-influenza drugs...However, there are still discussions related to the duration of prophylaxis, with shorter periods of administration being explored, or the most efficient treatment dosage program (whether it is the conventional dosage of 3 mg/kg/dose for children <40 kg or 75 mg for adults, twice daily, compared to a double dosage administration program). When faced with an old disease, it is essential to constantly assess the efficacy of conventional molecules and dosages, along with new antivirals or complementary medication."

Journal • Review • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

The Republic of Korea 2023-2024 Influenza and Respiratory Viruses Laboratory Surveillance Report (PubMed, Jugan Geongang Gwa Jilbyeong) - "Further, no mutations associated with resistance to antiviral drugs (Oseltamivir, Zanamivir, and Peramivir, Baloxavir) were identified...The continuous surveillance of influenza and respiratory virus trends is essential to inform vaccine strain selection and enhance public health response strategies. Our division will conduct continuous surveillance of the epidemiological trends of respiratory viruses, including influenza, and ensure the timely provision of data for public health interventions."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Clinical outcomes of baloxavir marboxil versus oseltamivir in outpatients aged 1 to under 5 years in China: a multicenter, retrospective cohort study. (PubMed, J Infect Chemother) - "BXM, the single-dose oral regimen, has demonstrated comparable effectiveness to OSV in terms of influenza-related return visits and hospitalization rates."

Clinical data • Journal • Retrospective data • Infectious Disease • Influenza • Respiratory Diseases

The Mechanism of Qing-Fei-Yin Decoction Against Influenza: Synergistical Inhibition on Viral Replication and Inflammation. (PubMed, J Ethnopharmacol) - "QFY Decoction exhibited experimentally validated anti-influenza activity, mediated primarily through three mechanisms: inhibition of viral replication, suppression of excessive inflammation, and modulation of intestinal microbiota balance."

Journal • Cough • Infectious Disease • Inflammation • Influenza • Respiratory Diseases • CCL2 • CXCL10 • IFNG • IL17A • IL6 • TNFA

Divergent Avian Influenza H10 Viruses from Sympatric Waterbird Species in Italy: Zoonotic Potential Assessment by Molecular Markers. (PubMed, Microorganisms) - "Moreover, phenotypic assay confirmed their susceptibility to oseltamivir and zanamivir drugs. From an ecological perspective, we found that different H10 gene pools seem to be harboured in different waterbird species sharing the same environment; additionally, a bidirectional transmission of H10 mallard isolates occurred between natural and anthropic ecosystems. Overall, our findings account for the need of continuous monitoring of AIVs belonging to the H10 subtype."

Biomarker • Journal • Infectious Disease • Influenza • Respiratory Diseases

Famotidine-Induced Rash and Eosinophilia: A Case Report. (PubMed, Cureus) - "He initially received intravenous gentamicin followed by oral amoxicillin-clavulanic acid for the urinary tract infection. Oseltamivir and carbocisteine were prescribed for the flu...Considering the timing of the rash and the patient's lack of prior adverse reactions to penicillin, famotidine was identified as the most probable causative agent for the rash. The rash improved following discontinuation of famotidine, supporting the diagnosis of famotidine-induced hypersensitivity reaction."

Journal • Allergy • Cardiovascular • Eosinophilia • Heart Failure • Immunology • Infectious Disease • Influenza • Nephrology • Respiratory Diseases

Risk Factors for Prolonged Viral Shedding in Hospitalized Influenza A Patients Treated with Oseltamivir: A Retrospective Cohort Study (APSR 2025) - "Conclusion : Early initiation of antiviral therapy and targeted management strategies for high-risk groups, particularly COPD patients, are critical to reducing the duration of viral shedding. The high prevalence of afebrile presentations in COPD patients highlights the necessity for routine influenza testing during respiratory exacerbations, irrespective of fever status."

Retrospective data • Chronic Obstructive Pulmonary Disease • CNS Disorders • Immunology • Infectious Disease • Influenza • Respiratory Diseases • Vascular Neurology

Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A (clinicaltrials.gov) - P3 | N=114 | Not yet recruiting | Sponsor: Guangdong Raynovent Biotech Co., Ltd

New P3 trial • Infectious Disease • Influenza • Respiratory Diseases

The Unprecedented Influenza Epidemic of 2024/2025: Overshadowing the COVID-19 Winter Wave and Exploring Viral Interference. (PubMed, Immun Inflamm Dis) - "We advocate enhanced surveillance, adopting wastewater monitoring as demonstrated in the U.S., and integrated vaccination campaigns with combined influenza-COVID-19 vaccines, currently in phase III trials, to boost immunity. Resource allocation, informed by the 2024/2025 hospital overload, is essential to manage surges. This article underscores the need for global coordination to understand viral interference and prepare for shifting respiratory virus dynamics, offering actionable strategies to mitigate future epidemics, including those caused by other viruses."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting (clinicaltrials.gov) - P3 | N=384 | Not yet recruiting | Sponsor: Capital Medical University

New P3 trial • Infectious Disease • Influenza • Respiratory Diseases

ZX-7101A-214: Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (clinicaltrials.gov) - P3 | N=168 | Recruiting | Sponsor: Nanjing Zenshine Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Obesity in Recovery From Influenza-Like Illness and Effectiveness of Oseltamivir. (PubMed, Influenza Other Respir Viruses) - "ILI symptom severity at presentation was equally distributed between the three weight groups. However, their time to recovery was approximately 1 day longer compared to under/normal weight patients. The effectiveness of oseltamivir appears to be similar between the two groups."

Clinical • Journal • Genetic Disorders • Infectious Disease • Influenza • Obesity • Respiratory Diseases

HLH Secondary to Influenza (ASH 2023) - "Oseltamivir was given for 5 days... We present this case to raise awareness among physicians regarding the potential occurrence of hemophagocytic lymphohistiocytosis (HLH) as a complication in adult patients who present with influenza B virus infection accompanied by fever and pancytopenia. The aim is to emphasize the importance of considering HLH as a differential diagnosis in order to facilitate timely identification and initiation of appropriate treatment for this condition."

Acute Respiratory Distress Syndrome • Anesthesia • Cough • Fatigue • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Rare Diseases • Respiratory Diseases • Rheumatology • CD8 • PRF1

Exploring the Anti-Influenza Activity of closo-Borate Platforms: Structure-Activity Relationship of Amino Acid-Functionalized closo-Dodecaborate Derivatives Against Influenza Virus A/Cheboksary/125/2020 (H1N1)pdm09. (PubMed, Molecules) - "Cross-platform comparison revealed that the dodecaborate-tryptophan conjugate Na22 exhibited comparable efficacy to its lead decaborate analog against the Orenburg strain while demonstrating potent activity (IC50 = 5.0 µg/mL) against the Cheboksary strain with reduced susceptibility to neuraminidase inhibitors (oseltamivir; zanamivir) and complete resistance to M2 channel blockers. The histidine-based conjugate Na23 also showed significant efficacy against the Cheboksary strain, while methionine and lactam derivatives (Na24; Na25) remained inactive. This work confirms boron clusters as versatile platforms for antiviral development and establishes structure-activity relationships crucial for optimizing both B10 and B12-based therapeutics against resistant influenza strains."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Transient Haemolytic Anaemia and Thrombocytopenia in a Healthy Young Adult Following Influenza a Infection. (PubMed, Eur J Case Rep Intern Med) - "Influenza A can precipitate Evans-like immune cytopaenias even in previously healthy young adults, a population not typically considered at risk for such haematologic complications.The presence of schistocytes can raise concern for thrombotic microangiopathy, but the absence of progressive renal or neurologic involvement should prompt consideration of immune-mediated cytopaenias.Early recognition and corticosteroid initiation can result in complete recovery without intravenous immunoglobulin (IVIG), rituximab or plasmapheresis, underscoring the importance of maintaining diagnostic vigilance in post-viral cytopaenias."

Journal • Acute Kidney Injury • Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Influenza • Nephrology • Pediatrics • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • HP

Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis. (PubMed, Front Microbiol) - "Additionally, the safety profiles of baloxavir and oseltamivir are comparable. https://www.crd.york.ac.uk/, CRD420251128843."

Journal • Retrospective data • Review • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

AIN't That the Flu Med? A Rare Case of Tamiflu-Induced Acute Interstitial Nephritis (AIN) (KIDNEY WEEK 2025) - "Prednisone therapy was initiated. This case also emphasizes the importance of renal dosing of Tamiflu in patients with CKD. Renal biopsy showing peritubular neutrophils"

Clinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Hypertension • Infectious Disease • Influenza • Musculoskeletal Pain • Nephrology • Renal Disease • Respiratory Diseases